You're reading the free version. Trader adds the live tape and alerts.
Start tracking
AVTX Sale Disclosure
Doyle Mittie · SEC Form 4 · Filed Aug 12, 2026
Sale
Calculated transaction value
$13.58K
Doyle Mittie Chief Medical Officer
AVTX
Avalo Therapeutics
AVTX
Transaction date
Aug 10, 2026
Public filing date
Aug 12, 2026
Filing lag
Filed 2 days later
AVTX daily price context
Close on/before transaction
$19.77
Aug 10, 2026
First close after public filing
$19.45
Aug 13, 2026
30-day return after filing
-17.12%
Through Sep 11, 2026
Source details
- Reported owner
- Not disclosed
- Source asset code
- Security
- Security
- Common Stock
- Quantity / price
- 679 shares @ $20
- SEC ownership
- Direct
- Transaction code
- S
- Form
- 4
- Filing identifier
- 0001918845-26-000026
Filing cohort
Transactions in this filing
Showing 3 of 3
Trades
3
Issuers
1
Estimated value
$19.04K
Buys / sales
0 / 1
| Issuer | Transaction | Traded | Value |
|---|---|---|---|
| Avalo Therapeutics, Inc. AVTX | Exercise | Aug 10, 2026 | $5.46K |
| Avalo Therapeutics, Inc. AVTX Current | Sale | Aug 10, 2026 | $13.58K |
| Avalo Therapeutics, Inc. AVTX | Exercise | Aug 10, 2026 | $0 |